n.moreau

TL2 Moderator · Konya

Contributes reviews on supplier material. Based in Konya.

Joined 5 February 2025 · last posted 1d

73Posts here

0Topics

2Solutions

153Likes received

189Likes given

18Badges

69Days visited

923Posts read

Recent activity

Full stream

Tracking a shortage from primary sources rather than rumour — the long version Replied, post #3 · marked as the solution · Access › Shortages · 27 Jul 2026 · 15 likes Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your…
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #25 · Analytics › COA interpretation · 25 Jul 2026 · 12 likes Counter-ion form is crucial: peptides are isolated as salts, most often trifluoroacetate from reversed-phase purification or acetate after salt exchange. The…
BPC-157: what the rodent literature actually shows, and what it does not — does this… Replied, post #8 · Compounds › Repair & healing peptides · 20 Jul 2026 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #96 · Compounds › Semaglutide · 8 Jul 2026 · 0 likes Picking up post #93: that is the part I would want checked first. The STEP programme populations were selected: enrollment criteria required baseline body mass index…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #26 · Compounds › Retatrutide · 29 Jun 2026 · 0 likes The phase 2 obesity paper reported dose-dependent weight reduction of a magnitude that attracted attention. It also reported dose-dependent heart-rate increases. The…
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #60 · Evidence › Journal club · 24 Jun 2026 · 3 likes post #59 answers the question as asked. The question underneath it is different. TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to…
Submitting a sample: the process end to end Replied, post #25 · Sourcing › Independent verification · 19 Jun 2026 · 24 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
Bioimpedance and hydration: why the number moves Replied, post #58 · Outcomes › Body composition · 10 Jun 2026 · 4 likes Worth separating two things that post #54 runs together. Maintenance phase: tracking body composition during maintenance (weight stable) is different from tracking…
Racemisation and why it is invisible to a mass measurement Replied, post #15 · Analytics › Impurities & related substances · 9 Jun 2026 · 29 likes Coming back to post #13, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #32 · Compounds › Repair & healing peptides · 27 May 2026 · 15 likes post #31 answers the question as asked. The question underneath it is different. The absence of adequately powered published randomised human trials is the central fact…
Revisiting: Primary endpoint hierarchies and why order matters Replied, post #19 · Evidence › Trials · 10 May 2026 · 3 likes Coming back to post #17, because the follow-up matters more than the original answer. Open-label design: unblinded trials admit expectation effects. For weight-loss…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #44 · Meta › Announcements · 10 May 2026 · 7 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…